ETFs to Profit from the Weight Loss Drug Boom
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Investing Themes: AI and weight-loss drugs have been dominant investing themes over the past year, with companies like NVIDIA in AI and Eli Lilly and Novo Nordisk in weight-loss drugs experiencing surges in their stock prices.
- Obesity Statistics: More than 1 billion individuals worldwide are living with obesity, a number expected to impact over half the population by 2035, leading to various health risks.
- GLP-1 Medications: GLP-1 drugs mimic a naturally occurring hormone and have shown benefits beyond diabetes treatment, including controlling blood sugar levels, reducing appetite, promoting weight loss, and potentially slowing Parkinson's symptoms.
- Market Growth: The market for weight-loss drugs, particularly GLP-1 medications, could surge to $130 billion by 2030, with Eli Lilly and Novo Nordisk projected to retain about 80% of the market share.
- Future Developments: There are 232 anti-obesity medications in development stages, aiming to reduce costs and common side effects of current drugs, such as nausea and muscle loss.
Analyst Views on THNR
Wall Street analysts forecast THNR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for THNR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 26.436
Low
Averages
High
Current: 26.436
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
